MENU
CTKB
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

CTKB stock forecast, quote, news & analysis

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells... Show more

CTKB
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for CTKB with price predictions
Oct 01, 2026

CTKB's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for CTKB turned positive on September 15, 2026. Looking at past instances where CTKB's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 14, 2026. You may want to consider a long position or call options on CTKB as a result. In 56 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

CTKB moved above its 50-day moving average on September 11, 2026 date and that indicates a change from a downward trend to an upward trend.

The 50-day moving average for CTKB moved above the 200-day moving average on September 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +3.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTKB advanced for three days, in 226 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

The Aroon Indicator entered an Uptrend today. In 96 of 145 cases where CTKB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

CTKB broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. CTKB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.317) is normal, around the industry mean (10.853). CTKB has a moderately high P/E Ratio (370.370) as compared to the industry average of (98.910). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.064) is also within normal values, averaging (39.828).

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTKB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 5.55B. The market cap for tickers in the group ranges from 837 to 174.73B. ABT holds the highest valuation in this group at 174.73B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -3%. QSI experienced the highest price growth at 82%, while GCTK experienced the biggest fall at -45%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 44%. For the same stocks of the Industry, the average monthly volume growth was 85% and the average quarterly volume growth was 101%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 74
Price Growth Rating: 63
SMR Rating: 89
Profit Risk Rating: 95
Seasonality Score: 11 (-100 ... +100)
View a ticker or compare two or three
CTKB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
47215 Lakeview Boulevard
Phone
+1 877 922-9835
Employees
702
Web
https://www.cytekbio.com
CTKB's MACD Histogram crosses above signal line